The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls.

Kahal H, Aburima A, Ungvari T, Rigby AS, Coady AM, Vince RV, Ajjan RA, Kilpatrick ES, Naseem KM, Atkin SL

BMC endocrine disorders2 Apr 2015Cited by 59 (Europe PMC)

PMID25880805PMCIDPMC4389314DOI10.1186/s12902-015-0005-6PepBankPUB-25880805

Summary

BackgroundPolycystic ovary syndrome (PCOS) is associated with obesity and increased cardiovascular (CV) risk markers. In this study our aim was to assess the effects of six months treatment with liraglutide 1.8 mg od on obesity, and CV risk markers, particularly platelet function, in young obese women with PCOS compared to controls of similar age and weight.MethodsCarotid intima-media wall thickness (cIMT) was measured by B-mode ultrasonography, platelet function by flow cytometry, clot structure/lysis by turbidimetric assays and endothelial function by ELISA and post-ischaemic reactive hyperemia (RHI). Data presented as mean change (6-month - baseline) ± standard deviation.ResultsNineteen obese women with PCOS and 17 controls, of similar age and weight, were recruited; baseline atherothrombotic risk markers did not differ between the two groups. Twenty five (69.4%) participants completed the study (13 PCOS, 12 controls). At six months, weight was significantly reduced by 3.0 ± 4.2 and 3.8 ± 3.4 kg in the PCOS and control groups, respectively; with no significant difference between the two groups, P = 0.56. Similarly, HOMA-IR, triglyceride, hsCRP, urinary isoprostanes, serum endothelial adhesion markers (sP-selectin, sICAM and sVCAM), and clot lysis area were equally significantly reduced in both groups compared to baseline. Basal platelet P-selectin expression was significantly reduced at six months in controls -0.17 ± 0.26 but not PCOS -0.12 ± 0.28; between groups difference, 95% confidence interval = -0.14 - 0.26, P = 0.41. No significant changes were noted in cIMT or RHI.ConclusionsSix months treatment with liraglutide (1.8 mg od) equally affected young obese women with PCOS and controls. In both groups, liraglutide treatment was associated with 3-4% weight loss and significant reduction in atherothrombosis markers including inflammation, endothelial function and clotting. Our data support the use of liraglutide as weight loss medication in simple obesity and suggest a potential beneficial effect on platelet function and atherothrombotic risk at 6 months of treatment.Trial registrationClinical trial reg. no. ISRCTN48560305. Date of registration 22/05/2012.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study16

16 results from studies that gave the peptide. 16 results from people.

01HumanNon-randomized trialEfficacy outcome
Weight loss with liraglutide did not differ significantly between women with PCOS and controls (P = 0.56).
In plain wordsWeight loss with liraglutide was similar in women with PCOS and in controls.
Peptide
Liraglutide
Outcome
No significant changeWeight change, difference between PCOS and control groups
Study
n = 25
Comparator
Controls without PCOS
Outcome group
Body weight · Metabolic and weight
Studied dose
1.8 mg od · 6 monthsAs given in this study (human).
Source sentences
Summary
At six months, weight was significantly reduced by 3.0 ± 4.2 and 3.8 ± 3.4 kg in the PCOS and control groups, respectively; with no significant difference between the two groups, P = 0.56.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study our aim was to assess the effects of six months treatment with liraglutide 1.8 mg od on obesity, and CV risk markers, particularly platelet function, in young obese women with PCOS compared to controls of similar age and weight.
Summary · context
Nineteen obese women with PCOS and 17 controls, of similar age and weight, were recruited; baseline atherothrombotic risk markers did not differ between the two groups.
Show in the study text Report a problemFND-2588080503
02HumanNon-randomized trialEfficacy outcome
In young obese women with PCOS and in controls, liraglutide equally and significantly reduced HOMA-IR from baseline.
In plain wordsIn young obese women with and without PCOS, liraglutide was linked to lower insulin resistance, to a similar degree.
Peptide
Liraglutide
Outcome
DecreaseHOMA-IR
Study
n = 25
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg od · 6 monthsAs given in this study (human).
Source sentences
Summary
Similarly, HOMA-IR, triglyceride, hsCRP, urinary isoprostanes, serum endothelial adhesion markers (sP-selectin, sICAM and sVCAM), and clot lysis area were equally significantly reduced in both groups compared to baseline.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study our aim was to assess the effects of six months treatment with liraglutide 1.8 mg od on obesity, and CV risk markers, particularly platelet function, in young obese women with PCOS compared to controls of similar age and weight.
Summary · context
Nineteen obese women with PCOS and 17 controls, of similar age and weight, were recruited; baseline atherothrombotic risk markers did not differ between the two groups.
Show in the study text Report a problemFND-2588080504
03HumanNon-randomized trialEfficacy outcome
In young obese women with PCOS and in controls, liraglutide equally and significantly reduced triglyceride from baseline.
In plain wordsIn young obese women with and without PCOS, liraglutide was linked to lower triglycerides, to a similar degree.
Peptide
Liraglutide
Outcome
DecreaseTriglyceride
Study
n = 25
Outcome group
Lipids · Metabolic and weight
Studied dose
1.8 mg od · 6 monthsAs given in this study (human).
Source sentences
Summary
Similarly, HOMA-IR, triglyceride, hsCRP, urinary isoprostanes, serum endothelial adhesion markers (sP-selectin, sICAM and sVCAM), and clot lysis area were equally significantly reduced in both groups compared to baseline.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study our aim was to assess the effects of six months treatment with liraglutide 1.8 mg od on obesity, and CV risk markers, particularly platelet function, in young obese women with PCOS compared to controls of similar age and weight.
Summary · context
Nineteen obese women with PCOS and 17 controls, of similar age and weight, were recruited; baseline atherothrombotic risk markers did not differ between the two groups.
Show in the study text Report a problemFND-2588080505
04HumanNon-randomized trialEfficacy outcome
In young obese women with PCOS and in controls, liraglutide equally and significantly reduced hsCRP from baseline.
In plain wordsIn young obese women with and without PCOS, liraglutide was linked to a lower inflammation marker, to a similar degree.
Peptide
Liraglutide
Outcome
DecreasehsCRP
Study
n = 25
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
1.8 mg od · 6 monthsAs given in this study (human).
Source sentences
Summary
Similarly, HOMA-IR, triglyceride, hsCRP, urinary isoprostanes, serum endothelial adhesion markers (sP-selectin, sICAM and sVCAM), and clot lysis area were equally significantly reduced in both groups compared to baseline.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study our aim was to assess the effects of six months treatment with liraglutide 1.8 mg od on obesity, and CV risk markers, particularly platelet function, in young obese women with PCOS compared to controls of similar age and weight.
Summary · context
Nineteen obese women with PCOS and 17 controls, of similar age and weight, were recruited; baseline atherothrombotic risk markers did not differ between the two groups.
Show in the study text Report a problemFND-2588080506
05HumanNon-randomized trialEfficacy outcome
In young obese women with PCOS and in controls, liraglutide equally and significantly reduced urinary isoprostanes from baseline.
In plain wordsIn young obese women with and without PCOS, liraglutide was linked to lower urinary isoprostanes, a stress marker, to a similar degree.
Peptide
Liraglutide
Outcome
DecreaseUrinary isoprostanes
Study
n = 25
Outcome group
Inflammation markers · Cardiovascular
Studied dose
1.8 mg od · 6 monthsAs given in this study (human).
Source sentences
Summary
Similarly, HOMA-IR, triglyceride, hsCRP, urinary isoprostanes, serum endothelial adhesion markers (sP-selectin, sICAM and sVCAM), and clot lysis area were equally significantly reduced in both groups compared to baseline.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study our aim was to assess the effects of six months treatment with liraglutide 1.8 mg od on obesity, and CV risk markers, particularly platelet function, in young obese women with PCOS compared to controls of similar age and weight.
Summary · context
Nineteen obese women with PCOS and 17 controls, of similar age and weight, were recruited; baseline atherothrombotic risk markers did not differ between the two groups.
Show in the study text Report a problemFND-2588080507
06HumanNon-randomized trialEfficacy outcome
In young obese women with PCOS and in controls, liraglutide equally and significantly reduced serum sP-selectin from baseline.
In plain wordsIn young obese women with and without PCOS, liraglutide was linked to lower sP-selectin, a blood vessel marker, to a similar degree.
Peptide
Liraglutide
Outcome
DecreaseSerum sP-selectin
Study
n = 25
Outcome group
Inflammation markers · Cardiovascular
Studied dose
1.8 mg od · 6 monthsAs given in this study (human).
Source sentences
Summary
Similarly, HOMA-IR, triglyceride, hsCRP, urinary isoprostanes, serum endothelial adhesion markers (sP-selectin, sICAM and sVCAM), and clot lysis area were equally significantly reduced in both groups compared to baseline.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study our aim was to assess the effects of six months treatment with liraglutide 1.8 mg od on obesity, and CV risk markers, particularly platelet function, in young obese women with PCOS compared to controls of similar age and weight.
Summary · context
Nineteen obese women with PCOS and 17 controls, of similar age and weight, were recruited; baseline atherothrombotic risk markers did not differ between the two groups.
Show in the study text Report a problemFND-2588080508
07HumanNon-randomized trialEfficacy outcome
In young obese women with PCOS and in controls, liraglutide equally and significantly reduced serum sICAM from baseline.
In plain wordsIn young obese women with and without PCOS, liraglutide was linked to lower sICAM, a blood vessel marker, to a similar degree.
Peptide
Liraglutide
Outcome
DecreaseSerum sICAM
Study
n = 25
Outcome group
Inflammation markers · Cardiovascular
Studied dose
1.8 mg od · 6 monthsAs given in this study (human).
Source sentences
Summary
Similarly, HOMA-IR, triglyceride, hsCRP, urinary isoprostanes, serum endothelial adhesion markers (sP-selectin, sICAM and sVCAM), and clot lysis area were equally significantly reduced in both groups compared to baseline.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study our aim was to assess the effects of six months treatment with liraglutide 1.8 mg od on obesity, and CV risk markers, particularly platelet function, in young obese women with PCOS compared to controls of similar age and weight.
Summary · context
Nineteen obese women with PCOS and 17 controls, of similar age and weight, were recruited; baseline atherothrombotic risk markers did not differ between the two groups.
Show in the study text Report a problemFND-2588080509
08HumanNon-randomized trialEfficacy outcome
In young obese women with PCOS and in controls, liraglutide equally and significantly reduced serum sVCAM from baseline.
In plain wordsIn young obese women with and without PCOS, liraglutide was linked to lower sVCAM, a blood vessel marker, to a similar degree.
Peptide
Liraglutide
Outcome
DecreaseSerum sVCAM
Study
n = 25
Outcome group
Inflammation markers · Cardiovascular
Studied dose
1.8 mg od · 6 monthsAs given in this study (human).
Source sentences
Summary
Similarly, HOMA-IR, triglyceride, hsCRP, urinary isoprostanes, serum endothelial adhesion markers (sP-selectin, sICAM and sVCAM), and clot lysis area were equally significantly reduced in both groups compared to baseline.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study our aim was to assess the effects of six months treatment with liraglutide 1.8 mg od on obesity, and CV risk markers, particularly platelet function, in young obese women with PCOS compared to controls of similar age and weight.
Summary · context
Nineteen obese women with PCOS and 17 controls, of similar age and weight, were recruited; baseline atherothrombotic risk markers did not differ between the two groups.
Show in the study text Report a problemFND-2588080510
09HumanNon-randomized trialEfficacy outcome
In young obese women with PCOS and in controls, liraglutide equally and significantly reduced clot lysis area from baseline.
In plain wordsIn young obese women with and without PCOS, liraglutide was linked to a smaller clot lysis area, to a similar degree.
Peptide
Liraglutide
Outcome
DecreaseClot lysis area
Study
n = 25
Outcome group
Bleeding and clotting · Cardiovascular
Studied dose
1.8 mg od · 6 monthsAs given in this study (human).
Source sentences
Summary
Similarly, HOMA-IR, triglyceride, hsCRP, urinary isoprostanes, serum endothelial adhesion markers (sP-selectin, sICAM and sVCAM), and clot lysis area were equally significantly reduced in both groups compared to baseline.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study our aim was to assess the effects of six months treatment with liraglutide 1.8 mg od on obesity, and CV risk markers, particularly platelet function, in young obese women with PCOS compared to controls of similar age and weight.
Summary · context
Nineteen obese women with PCOS and 17 controls, of similar age and weight, were recruited; baseline atherothrombotic risk markers did not differ between the two groups.
Show in the study text Report a problemFND-2588080511
10HumanNon-randomized trialEfficacy outcome
The change in basal platelet P-selectin expression did not differ significantly between women with PCOS and controls (P = 0.41).
In plain wordsThe change in platelet P-selectin with liraglutide was not significantly different between women with PCOS and controls.
Peptide
Liraglutide
Outcome
No significant changeBasal platelet P-selectin expression, difference between groups
Study
n = 25
Comparator
Controls without PCOS
Outcome group
Bleeding and clotting · Cardiovascular
Studied dose
1.8 mg od · 6 monthsAs given in this study (human).
Source sentences
Summary
Basal platelet P-selectin expression was significantly reduced at six months in controls -0.17 ± 0.26 but not PCOS -0.12 ± 0.28; between groups difference, 95% confidence interval = -0.14 - 0.26, P = 0.41.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study our aim was to assess the effects of six months treatment with liraglutide 1.8 mg od on obesity, and CV risk markers, particularly platelet function, in young obese women with PCOS compared to controls of similar age and weight.
Summary · context
Nineteen obese women with PCOS and 17 controls, of similar age and weight, were recruited; baseline atherothrombotic risk markers did not differ between the two groups.
Show in the study text Report a problemFND-2588080514
11HumanNon-randomized trialEfficacy outcome
In young obese women with PCOS and in controls, six months of liraglutide caused no significant change in carotid intima-media thickness.
In plain wordsIn young obese women with and without PCOS, liraglutide caused no significant change in the thickness of the carotid artery wall.
Peptide
Liraglutide
Outcome
No significant changeCarotid intima-media wall thickness (cIMT)
Study
n = 25
Outcome group
Vascular function · Cardiovascular
Studied dose
1.8 mg od · 6 monthsAs given in this study (human).
Source sentences
Summary
No significant changes were noted in cIMT or RHI.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study our aim was to assess the effects of six months treatment with liraglutide 1.8 mg od on obesity, and CV risk markers, particularly platelet function, in young obese women with PCOS compared to controls of similar age and weight.
Summary · context
Nineteen obese women with PCOS and 17 controls, of similar age and weight, were recruited; baseline atherothrombotic risk markers did not differ between the two groups.
Show in the study text Report a problemFND-2588080515
12HumanNon-randomized trialEfficacy outcome
In young obese women with PCOS and in controls, six months of liraglutide caused no significant change in reactive hyperemia index.
In plain wordsIn young obese women with and without PCOS, liraglutide caused no significant change in a blood vessel function test.
Peptide
Liraglutide
Outcome
No significant changePost-ischaemic reactive hyperemia index (RHI)
Study
n = 25
Outcome group
Vascular function · Cardiovascular
Studied dose
1.8 mg od · 6 monthsAs given in this study (human).
Source sentences
Summary
No significant changes were noted in cIMT or RHI.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study our aim was to assess the effects of six months treatment with liraglutide 1.8 mg od on obesity, and CV risk markers, particularly platelet function, in young obese women with PCOS compared to controls of similar age and weight.
Summary · context
Nineteen obese women with PCOS and 17 controls, of similar age and weight, were recruited; baseline atherothrombotic risk markers did not differ between the two groups.
Show in the study text Report a problemFND-2588080516
13HumanNon-randomized trialEfficacy outcome
In young obese women with PCOS, six months of liraglutide significantly reduced weight.
In plain wordsIn young obese women with PCOS, six months of liraglutide was linked to weight loss.
Peptide
Liraglutide
Outcome
DecreaseWeight change, PCOS group
Study
n = 13
Outcome group
Body weight · Metabolic and weight
Studied dose
1.8 mg od · 6 monthsAs given in this study (human).
Measurements
Weight change
−3 kg
PCOS group
Source sentences
Summary
At six months, weight was significantly reduced by 3.0 ± 4.2 and 3.8 ± 3.4 kg in the PCOS and control groups, respectively; with no significant difference between the two groups, P = 0.56.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study our aim was to assess the effects of six months treatment with liraglutide 1.8 mg od on obesity, and CV risk markers, particularly platelet function, in young obese women with PCOS compared to controls of similar age and weight.
Summary · context
Nineteen obese women with PCOS and 17 controls, of similar age and weight, were recruited; baseline atherothrombotic risk markers did not differ between the two groups.
Show in the study text Report a problemFND-2588080501
14HumanNon-randomized trialEfficacy outcome
In young obese women with PCOS, basal platelet P-selectin expression was not significantly reduced after six months of liraglutide.
In plain wordsIn young obese women with PCOS, liraglutide did not significantly lower platelet P-selectin, a clotting marker.
Peptide
Liraglutide
Outcome
No significant changeBasal platelet P-selectin expression, PCOS group
Study
n = 13
Outcome group
Bleeding and clotting · Cardiovascular
Studied dose
1.8 mg od · 6 monthsAs given in this study (human).
Source sentences
Summary
Basal platelet P-selectin expression was significantly reduced at six months in controls -0.17 ± 0.26 but not PCOS -0.12 ± 0.28; between groups difference, 95% confidence interval = -0.14 - 0.26, P = 0.41.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study our aim was to assess the effects of six months treatment with liraglutide 1.8 mg od on obesity, and CV risk markers, particularly platelet function, in young obese women with PCOS compared to controls of similar age and weight.
Summary · context
Nineteen obese women with PCOS and 17 controls, of similar age and weight, were recruited; baseline atherothrombotic risk markers did not differ between the two groups.
Show in the study text Report a problemFND-2588080513
15HumanNon-randomized trialEfficacy outcome
In young obese control women without PCOS, six months of liraglutide significantly reduced weight.
In plain wordsIn young obese women without PCOS, six months of liraglutide was linked to weight loss.
Peptide
Liraglutide
Outcome
DecreaseWeight change, control group
Study
n = 12
Outcome group
Body weight · Metabolic and weight
Studied dose
1.8 mg od · 6 monthsAs given in this study (human).
Measurements
Weight change
−3.8 kg
control group
Source sentences
Summary
At six months, weight was significantly reduced by 3.0 ± 4.2 and 3.8 ± 3.4 kg in the PCOS and control groups, respectively; with no significant difference between the two groups, P = 0.56.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study our aim was to assess the effects of six months treatment with liraglutide 1.8 mg od on obesity, and CV risk markers, particularly platelet function, in young obese women with PCOS compared to controls of similar age and weight.
Summary · context
Nineteen obese women with PCOS and 17 controls, of similar age and weight, were recruited; baseline atherothrombotic risk markers did not differ between the two groups.
Show in the study text Report a problemFND-2588080502
16HumanNon-randomized trialEfficacy outcome
In young obese control women, basal platelet P-selectin expression was significantly reduced after six months of liraglutide.
In plain wordsIn young obese women without PCOS, liraglutide was linked to lower platelet P-selectin, a clotting marker.
Peptide
Liraglutide
Outcome
DecreaseBasal platelet P-selectin expression, control group
Study
n = 12
Outcome group
Bleeding and clotting · Cardiovascular
Studied dose
1.8 mg od · 6 monthsAs given in this study (human).
Source sentences
Summary
Basal platelet P-selectin expression was significantly reduced at six months in controls -0.17 ± 0.26 but not PCOS -0.12 ± 0.28; between groups difference, 95% confidence interval = -0.14 - 0.26, P = 0.41.
2 context sentences(design, population, supporting numbers)
Summary · context
In this study our aim was to assess the effects of six months treatment with liraglutide 1.8 mg od on obesity, and CV risk markers, particularly platelet function, in young obese women with PCOS compared to controls of similar age and weight.
Summary · context
Nineteen obese women with PCOS and 17 controls, of similar age and weight, were recruited; baseline atherothrombotic risk markers did not differ between the two groups.
Show in the study text Report a problemFND-2588080512

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT03352869

Research of Exenatide for Overweight/Obese PCOS Patients With IGR

RenJi Hospitaln = 18328 Nov 2017 to 31 Jul 2018

Polycystic Ovary Syndrome · Overweight and Obesity · Disorder of Glucose Regulation

Trial page ClinicalTrials.govUpdated 11 Sept 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.